Pfizer Revenue and Competitors
Estimated Revenue & Valuation
- Pfizer's estimated annual revenue is currently $69.3B per year.
- Pfizer's estimated revenue per employee is $615,393
- Pfizer's current valuation is $308.4B. (January 2022)
Employee Data
- Pfizer has 112676 Employees.
- Pfizer grew their employee count by 4% last year.
Pfizer's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman and CEO | Reveal Email/Phone |
2 | EA to Chairman and CEO | Reveal Email/Phone |
3 | Senior Director, NYHQ Site Engagement Lead | Office the Chairman & CEO | Reveal Email/Phone |
4 | Director Executive Operations, Office the CEO | Reveal Email/Phone |
5 | Chief Staff | Reveal Email/Phone |
6 | VP and Chief Toxicology Scientist | Reveal Email/Phone |
7 | LACES CDAS & DA System Owner | Reveal Email/Phone |
8 | owner | Reveal Email/Phone |
9 | Chief Strategy and Innovation Officer, EVP | Reveal Email/Phone |
10 | Interim Chief Oncology Officer, Pfizer Oncology | Reveal Email/Phone |
Pfizer Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11830M | 9797 | 26% | $2.7B | $83B |
#2 | $32820M | 100973 | 7% | N/A | $182.4B |
#3 | $18.3M | 91 | 14% | N/A | N/A |
What Is Pfizer?
Pfizer Inc discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health and consumer health care. Our products are available in more than 150 countries.
keywords:Biotechnology
N/A
Total Funding
112676
Number of Employees
$69.3B
Revenue (est)
4%
Employee Growth %
$308.4B
Valuation
N/A
Accelerator
Pfizer News
Reports of two patients who found relief from long COVID after taking Pfizer Inc's antiviral Paxlovid, including a researcher who tested it...
Worldwide demand for Pfizer Inc's oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to complicated eligibility...
Reports of two patients who found relief from long COVID after taking Pfizer Inc's antiviral Paxlovid, including a researcher who tested it...
Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia Study met its primary endpoint, achieving a statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C) - as well as a statistically significant r ...
NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commerc ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $131180M | 161444 | N/A | N/A |
#2 | $47529.8M | 161666 | N/A | N/A |
#3 | $59040.5M | 191690 | 8% | N/A |
#4 | $74990M | 211976 | 5% | N/A |
#5 | $273.8M | 224062 | 11% | $111M |